NEW | EMA update on Q&As for biological medicinal products

October 3, 2023

EMA has issued an update on the Questions and Answers for biological human medicinal products, providing agreed positions by the Biologics Working Party on issues that can be subject to different interpretation or require clarification, typically arising from discussions or correspondence during assessment procedures of biological human medicinal products.

The topics covered include, among others:

  • Reprocessing (3.2.S.2.2, 3.2.P.3.3)
  • Raw materials and media components (3.2.S.2.3)
  • Method identification numbers (3.2.S.4.1, 3.2.P.5.1)
  • Process validation, removal of process related impurities, process related impurities testing (3.2.S.2.5, 3.2.P.3.5)
  • Host cell proteins testing, drug substance specification (3.2.S.3.2, 3.2.S.4.1, 3.2.S.4.5)
  • Biosimilar medicinal products: characterization, side-by-side comparison, specification, biosimilarity, analytical comparability (3.2.S, 3.2.S.3.1, 3.2.S.4.1, 3.2.P.5.1, 3.2.R)

 

You can have a look at the complete document here: Q&As for biological medicinal products EMA

At Asphalion, we are seasoned experts in CMC and we can support you in all your projects.

Contact us at: info@asphalion.com

Or schedule a free 30-minute meeting here: SCHEDULE A MEETING

Search News & Events

  • Filter by category

Share

Related news and events

EVENT | 20th Biosimilar Medicines Conference by MFE

During these two interactive days, actors of the healthcare community alongside world experts in biosimilar medicines will gather and debate the evolving biosimilar medicines landscape and emerging trends. Discussion will focus on sharing good practices and setting collective aims to achieve the depth, breadth and speed of the use of biosimilar medicines as a lever to untap their transformative value.

NEWS | ICH Q14 Guideline on analytical procedure development

This guideline describes science and risk-based approaches for developing and maintaining analytical procedures suitable for the evaluation of the quality of drug substances and drug products. It complements ICH Q2 Validation of Analytical Procedures.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting